Lymphangiogenesis for therapeutic immunomodulation
AssigneeThe University of Chicago
InventorsMelody A. Swartz, Jeffrey A. Hubbell, Shann Yu, Efthymia Vokali, Manuel Fankhauser, Sachiko Hirosue, Priscilla S. Briquez, Maria Broggi, Lambert Potin, Maria Stella Sasso
Life of this patent
Estimating the term…
Abstract
The present invention concerns methods and compositions for evoking protective immune responses against pathogen infection or cancer. In certain embodiments, the methods and compositions comprise a lymphangiogenesis inducer and an antigen.
Claims127
A method of eliciting an immune response to an antigen in a subject comprising administering to the subject one or more lymphangiogenesis inducers and an effective amount of the antigen.
A method of treating or preventing an infection in a subject, the method comprising administering to the subject an isolated lymphangiogenesis inducer and an effective amount of an antigen.
A pharmaceutical composition comprising one or more lymphangiogenesis inducers, an effective amount of an antigen and a pharmaceutically acceptable excipient.
A method of treating neoplasia, dysplasia or cancer, the method comprising administering to a subject one or more lymphangiogenesis inducers and an effective amount of one or more neoplasia, dysplasia or cancer antigens.
A method for treating a cancer patient with cancer immunotherapy comprising administering cancer immunotherapy to the patient after detecting in a serum sample from that patient a level of VEGF-C and/or CCL21 that is indicative of response to cancer immunotherapy.
A method for predicting the efficacy of cancer immunotherapy in a patient comprising:
- measuring a level of VEGF-C and/or CCL21 protein expression in a serum sample from the patient;
- and,
- comparing the level of VEGF-C and/or CCL21 protein expression to a level in a control sample.
Dependencies are inferred from the claim text.